Navigation Links
Olympus broadens portfolio with new biliary metallic stent

CENTER VALLEY, Pa., June 1, 2009 Olympus America Inc. today expanded its medical portfolio by introducing the X-Suit NIR, a biliary metallic stent designed with exceptional anatomic conformability and superior radial support. The X-Suit NIR's proprietary NIRflex cell design provides a physician support and flexibility; both critical to help relieve the symptoms associated with pancreatic, liver and bile duct cancers.

The NIRflex advanced cell design biliary metallic stent provides flexible construction to fit the shape of any biliary duct. Constructed of Nitinol, the stent is water-jet cut and electro-polished for much greater durability. Each strut is also rounded, helping to reduce stress to the tissue and prevent damage to the bile duct and duodenal walls.

"Olympus provides the most extensive line of GI products and services in the industry," said Eric Halvorson, chief marketing officer, Medical Systems Group, Olympus America, Inc. "X-Suit is a good example of how Olympus remains dedicated to expanding its offerings and working with the world's top medical experts to provide solutions that best suit the needs of its customers and their patients."

To ensure precise placement of the stent during a therapeutic procedure, the X-Suit NIR has virtually no foreshortening. In addition, each end of the stent features five radiopaque markers that allow physicians to determine the position of the stent under an X-ray prior to deployment. A black marker is positioned at the proximal end of the stent facilitating endoscopic confirmation of the stent during deployment. The ease of deployment combined with superior radial support makes the X-Suit NIR the stent of choice for re-establishing biliary flow.


Contact: Lisa Koen
Golin/Harris International

Page: 1

Related biology news :

1. Olympus advances technology for laparo-endoscopic single-site surgery
2. Lockheed Martin Advances Biometrics Portfolio Through Cooperation Agreement With Cognitec
3. Springer expands its portfolio in plant sciences with Phytoparasitica
4. 2 carotid artery stenting studies show results comparable to AHA guidelines
5. Massive California fires consistent with climate change
6. The Lancet publishes first clinical trial data of a fully bioabsorbable drug eluting stent
7. Persistent man-made chemical pollutants found in deep-sea octopods and squids
8. Stent grafts: a better way to treat blunt trauma injuries
9. Goulbourne earns NSF award to research heart stent sensors
10. 12-month ATLANTA trial data show sustained benefit of Catania Stent
11. Persistent pollutant may promote obesity
Post Your Comments:
Related Image:
Olympus broadens portfolio with new biliary metallic stent
(Date:6/2/2016)... LONDON , June 2, 2016 ... has awarded the 44 million US Dollar project, ... Security Embossed Vehicle Plates including Personalization, Enrolment, and IT Infrastructure ... world leader in the production and implementation of Identity Management ... in January, however Decatur was selected ...
(Date:5/20/2016)... , May 20, 2016  VoiceIt is excited ... with VoicePass. By working together, VoiceIt ...  Because VoiceIt and VoicePass take slightly different approaches ... increases both security and usability. ... about this new partnership. "This marketing ...
(Date:4/28/2016)... BANGALORE, India , April 28, 2016 ... of Infosys (NYSE: INFY ), and Samsung SDS, ... partnership that will provide end customers with a more ... payment services.      (Logo: ) ... financial services, but it also plays a fundamental part in ...
Breaking Biology News(10 mins):
(Date:6/23/2016)... ... 23, 2016 , ... STACS DNA Inc., the sample tracking software company, today ... Laboratory, has joined STACS DNA as a Field Application Specialist. , “I am ... and COO of STACS DNA. “In further expanding our capacity as a scientific integrator, ...
(Date:6/23/2016)... , June 23, 2016 Apellis Pharmaceuticals, ... 1 clinical trials of its complement C3 inhibitor, ... and multiple ascending dose studies designed to assess ... of subcutaneous injection in healthy adult volunteers. ... either as a single dose (ranging from 45 ...
(Date:6/23/2016)... , June 23, 2016 ... Hematology Review, 2016;12(1):22-8 ... , the peer-reviewed journal from touchONCOLOGY, Andrew ... escalating cost of cancer care is placing an ... result of expensive biologic therapies. With the patents ...
(Date:6/23/2016)... (PRWEB) , ... June 23, 2016 , ... ... is exhibiting at the Pennsylvania Convention Center and will showcase its product’s latest ... ClinCapture will also be presenting a scientific poster on Disrupting Clinical Trials in ...
Breaking Biology Technology: